Last reviewed · How we verify
NCT05352854
In Vivo Morphological Changes of Ciliary Body and Trabecular Meshwork in High Myopia Eyes With Open-angle Glaucoma in Their Accommodation Induced by Pilocarpine
NA trial testing 0.5% pilocarpine eye drops in Glaucoma in 120 participants. Status unknown.
1 June 2022
Quick facts
| Lead sponsor | Yune Zhao |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 120 |
| Start date | 1 May 2022 |
| Primary completion | 1 June 2022 |
| Estimated completion | 1 August 2022 |
Drugs / interventions tested
- 0.5% pilocarpine eye drops — full drug profile →
Conditions studied
Sponsor
Yune Zhao — full company profile →
Who can join
Adults 18 to 60, any sex, with Glaucoma or Myopia. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Morphology of ciliary body
Time frame: baseline, pre-intervention(local application of pilocarpine eye drops)
measurement of Morphology of ciliary body using CAISA2(The novel anterior segment optical coherence tomography (AS-OCT) device) and Image J software -
Morphology of ciliary body
Time frame: 40 minutes after the intervention(local application of pilocarpine eye drops)
measurement of Morphology of ciliary body using CAISA2(The novel anterior segment optical coherence tomography (AS-OCT) device) and Image J software -
Morphology of trabecular meshwork
Time frame: baseline, pre-intervention(local application of pilocarpine eye drops)
measurement of Morphology of trabecular meshwork using CAISA2(The novel anterior segment optical coherence tomography (AS-OCT) device) and Image J software -
Morphology of trabecular meshwork
Time frame: 40 minutes after the intervention(local application of pilocarpine eye drops)
measurement of Morphology of trabecular meshwork using CAISA2(The novel anterior segment optical coherence tomography (AS-OCT) device) and Image J software
Sponsor's own description
Glaucoma is the leading cause of irreversible blindness worldwide. Although the pathogenesis remains unclear, pathologic increase in intraocular pressure (IOP) due to blocked aqueous outflow through the trabecular-Schlemm canal is known to be an important risk factor, and reduction of IOP is the only clinically validated way to retard the progression of OAG. Ciliary muscle plays a central role in the trabecular meshwork-Schlemm canal outflow pathway. Clinical evidence suggests that ciliary muscle contraction stimulated by cholinergic receptor agonist and retraction of ciliary body position after cataract surgery can dilate the lumen of Schlemm canal and reduce IOP. Currently, Ultrasound biomicroscopy (UBM) can obtain two-dimensional images of the anterior segment using high-frequency Ultrasound transducers in medical imaging studies of the ciliary body - trabecular meshwork -Schlemm canal complex. UBM has better tissue penetration than Optical coherence tomography (OCT) and can image the ciliary body better, but it has a lower resolution (30um to 50um) and is poor at imaging tiny tissues such as trabecular meshwork and Schlemm canal. The latest swept-source OCT (SS-OCT) has faster image capture rate (1000000 A scans/SEC), stronger penetration and higher resolution (8um axial resolution and 20um transverse resolution). The structure and morphology of ciliary body-trabecular meshwork-Schlemm canal complex can be clearly photographed. The investigators intend to use CASIA2 to image the ciliary body-trabecular meshwork-Schlemm canal complex before and after administration of pilocarpine in healthy individuals and patients with glaucoma to assess the effect of pilocarpine on the anatomy of the ciliary body-trabecular meshwork-Schlemm canal complex.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Change of Ciliary Muscle-Trabecular Meshwork-Schlemm Canal Complex after Phacoemulsification using Swept-Source-Optical Coherence Tomography.
Li Z, Wu X, Ji X, Zhu Z, et al · · 2025 · PMID 39837299 · DOI 10.1159/000543303
Verify or expand the search:
- PubMed search for NCT05352854
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Glaucoma
Currently open trials in the same condition.
- NCT07455786 — Modified Trabeculectomy After Failure of Combined Phaco With GATT · NA · recruiting
- NCT07298356 — Automated Applanation Tonometry - Updated · NA · recruiting
- NCT07217678 — Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use · Phase 4 · recruiting
- NCT07145073 — Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies · NA · recruiting
- NCT07209410 — Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanopro · Phase 4 · recruiting
Other Yune Zhao trials
Trials by the same sponsor.
- NCT05594537 — The Best Way to Improve the Near Visual Acuity After ZXR00 IOL Implantation · unknown
- NCT05201677 — Improved Operation of Low Intraocular Pressure in Phacoemulsification for Patients With High Myopia Complicated With Cat · NA · unknown
- NCT04636372 — Effect of Meibomian Gland Related Therapy on the Morphology of Meibomian Gland · NA · withdrawn
- NCT04824755 — Reduced ER-QOL in Families After Congenital Cataract Surgery · NA · completed
- NCT04487795 — Age-related Changes of Crystalline Lens Tilt and Decentration: A Swept-source Optical Coherence Tomography Study · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05352854 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yune Zhao
- Last refreshed: 24 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05352854.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing